Healthcare
eXoZymes, Inc.(EXOZ)
Live Price
Offline$7.83
+23.70% today
1Y Change
-23.54%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $90.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -51.4%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
eXoZymes, Inc. (EXOZ) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $7.83 and down 23.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -51.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -51.4%, free cash flow +25.1% with operating margin 0.0% and ROIC -203.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EXOZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -51.4%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.6% | -6.2% | -29.1% |
2026 Mar 30, 2026 | โ | +2.9% | +37.1% | +41.4% |
2025 Nov 13, 2025 | โ | -7.0% | -3.0% | -12.6% |
Benchmark Edge
EXOZ vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EXOZ
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EXOZ Max Drawdown
-61.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EXOZ and SPY.
Company Overview
eXoZymes, Inc.
NASDAQ Global Market
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
- Leadership
- Michael Heltzen
- IPO Date
- Nov 13, 2024
- Employees
- 31
- Street Address
- 750 Royal Oaks Drive
- Mailing
- Monrovia, NV, 91016
- Region
- Monrovia, NV, US
- Reporting Currency
- USD
- Investor Line
- 626 415 1488
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 26.0
Growth
- Revenue
- 0.0%
- EPS
- -51.4%
- Free Cash Flow
- +25.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -147.2%
- ROIC
- -203.1%
Balance Sheet
- Debt/Equity
- 0.37
- Current Ratio
- 2.51
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.